Interview with Marco Cartolari, CEO, Scharper
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
Address: Viale Ortles, 12 – 20139 Milan (MI),Italy
Tel: +39.02.2629161
Web: http://www.scharper.it/introscharper.htm
Created in 1995 by Dr. Lino Cartolari as La Farmochimica Italiana Srl (LFI), the company then purchased Scharper trademark in 1996 and signs several licensing agreements with different pharma leaders.
Scharper now operates in selected therapeutic areas, and focuses on high profile prescription drugs
(primarily through in-licensing arrangements) as well as highly researched and clinically supported medical foods, nutraceuticals, cosmeceuticals and medical devices( to date developed primarily internally).
Scharper’s focus is unique in that it treats non-drug products with the same scientific scrutiny and rigour as drug products.
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
Dr Nicola Normanno, the Director of the Translational Research Department of one of Italy’s national cancer institutes, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, and president of the Italian Cancer…
Tiziana Mele, managing director of Lundbeck Italia, explains the impact of COVID on mental health care from the perspective of a company dedicated to brain health, outlines the Italian operation…
Guerbet’s Alessandro Bocci – General Manager Italy & Iberia – describes the nearly 100-year-old company’s firm position in the field of contrast media for radiology and its plans for developing…
Medtronic’s Michele Perrino, Regional VP North Western Europe & Italy, Cardiovascular Commercial Partnership WE, outlines the company’s change in positioning from medtech to healthcare technology and the central role of…
Giuseppe Maduri, Chairman, Managing Director, General Manager Italy, Greece, Cyprus, Malta at Astellas Pharma explains the Japanese company’s focus on unmet needs and how Italy, one of its top European…
Chairman & Managing Director of B. Braun Milano, Klaus D. Pannes, shares the importance of the German medtech’s Italian affiliate, one of its top ten by third-party sales, which is…
Paivi Kerkola, Country Manager, Managing Director and President of Pfizer Italy, speaks about the peculiarities of the Italian market from a northern European perspective, her priorities, and the impact of…
See our Cookie Privacy Policy Here
